Sunshine Biopharma is trading 6.6% down at $2.57 in pre-market, compared with its November 2 close of $2.75; no clear new catalyst was identified. - Price context shows a continued decline after two consecutive lower closes. - No November 3 company announcement was identified. The latest listed releases were the October 22 reverse-split announcement and October 9 public-offering closing; neither establishes a cause for the drop. - Broader market indicators are mixed, so a market-driven explanation is also unclear.